https://techilive.in/%e7%be%8e%e5%9b%bdfda%e6%89%b9%e5%87%86camzyos%ef%bc%88mavacamten%ef%bc%89%e7%94%a8%e4%ba%8e%e6%b2%bb%e7%96%97%e7%ba%bd%e7%ba%a6%e5%bf%83%e8%84%8f%e7%97%85%e5%8d%8f%e4%bc%9a%e5%bf%83%e5%8a%9f%e8%83%bd/
美国FDA批准Camzyos(mavacamten)用于治疗纽约心脏病协会心功能分级为II-III级的有症状梗阻性肥厚型心肌病成人患者以改善功能和症状